BACKGROUND: The main obstacle to elucidating the role of CD4(+) T cells in allergen-specific immunotherapy (SIT) has been the absence of an adequately sensitive approach to directly characterize rare allergen-specific T cells without introducing substantial phenotypic modifications by means of in vitro amplification. OBJECTIVE: We sought to monitor, in physiological conditions, the allergen-specific CD4(+) T cells generated during natural pollen exposure and during allergy vaccination. METHODS: Alder pollen allergy was used as a model for studying seasonal allergies. Allergen-specific CD4(+) T cells were tracked and characterized in 12 subjects with alder pollen allergy, 6 nonallergic subjects, and 9 allergy vaccine-treated subjects by using peptide-MHC class II tetramers. RESULTS: Allergen-specific CD4(+) T cells were detected in all of the subjects with alder pollen allergy and nonallergic subjects tested. Pathogenic responses--chemoattractant receptor homologous molecule expressed on T(H)2 lymphocytes (CRTH2) expression and T(H)2 cytokine production--are specifically associated with terminally differentiated (CD27(-)) allergen-specific CD4(+) T cells, which dominate in allergic subjects but are absent in nonallergic subjects. In contrast, CD27(+) allergen-specific CD4(+) T cells are present at low frequencies in both allergic and nonallergic subjects and reflect classical features of the protective immune response with high expression of IL-10 and IFN-γ. Restoration of a protective response during SIT appears to be due to the preferential deletion of pathogenic (CD27(-)) allergen-specific CD4(+) T cells accompanied by IL-10 induction in surviving CD27(+) allergen-specific CD4(+) T cells. CONCLUSIONS: Differentiation stage divides allergen-specific CD4(+) T cells into 2 distinct subpopulations with unique functional properties and different fates during SIT.
BACKGROUND: The main obstacle to elucidating the role of CD4(+) T cells in allergen-specific immunotherapy (SIT) has been the absence of an adequately sensitive approach to directly characterize rare allergen-specific T cells without introducing substantial phenotypic modifications by means of in vitro amplification. OBJECTIVE: We sought to monitor, in physiological conditions, the allergen-specific CD4(+) T cells generated during natural pollen exposure and during allergy vaccination. METHODS: Alder pollen allergy was used as a model for studying seasonal allergies. Allergen-specific CD4(+) T cells were tracked and characterized in 12 subjects with alder pollen allergy, 6 nonallergic subjects, and 9 allergy vaccine-treated subjects by using peptide-MHC class II tetramers. RESULTS: Allergen-specific CD4(+) T cells were detected in all of the subjects with alder pollen allergy and nonallergic subjects tested. Pathogenic responses--chemoattractant receptor homologous molecule expressed on T(H)2 lymphocytes (CRTH2) expression and T(H)2 cytokine production--are specifically associated with terminally differentiated (CD27(-)) allergen-specific CD4(+) T cells, which dominate in allergic subjects but are absent in nonallergic subjects. In contrast, CD27(+) allergen-specific CD4(+) T cells are present at low frequencies in both allergic and nonallergic subjects and reflect classical features of the protective immune response with high expression of IL-10 and IFN-γ. Restoration of a protective response during SIT appears to be due to the preferential deletion of pathogenic (CD27(-)) allergen-specific CD4(+) T cells accompanied by IL-10 induction in surviving CD27(+) allergen-specific CD4(+) T cells. CONCLUSIONS: Differentiation stage divides allergen-specific CD4(+) T cells into 2 distinct subpopulations with unique functional properties and different fates during SIT.
Authors: Ruth D Fritsch; Xinglei Shen; Gary P Sims; Karen S Hathcock; Richard J Hodes; Peter E Lipsky Journal: J Immunol Date: 2005-11-15 Impact factor: 5.422
Authors: Gunter Rappl; David Schrama; Andreas Hombach; Eva Katharina Meuer; Annette Schmidt; Jürgen C Becker; Hinrich Abken Journal: Rejuvenation Res Date: 2008-06 Impact factor: 4.663
Authors: Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani Journal: Nat Immunol Date: 2007-05-07 Impact factor: 25.606
Authors: Margarida Saraiva; Jillian R Christensen; Marc Veldhoen; Theresa L Murphy; Kenneth M Murphy; Anne O'Garra Journal: Immunity Date: 2009-07-30 Impact factor: 31.745
Authors: John F Ryan; Rachel Hovde; Jacob Glanville; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Robert J Tibshirani; David C Jay; Scott D Boyd; R Sharon Chinthrajah; Mark M Davis; Stephen J Galli; Holden T Maecker; Kari C Nadeau Journal: Proc Natl Acad Sci U S A Date: 2016-01-25 Impact factor: 11.205
Authors: Anssi Kailaanmäki; Tuure Kinnunen; William W Kwok; Marja Rytkönen-Nissinen; Jukka Randell; Tuomas Virtanen Journal: Immunology Date: 2014-01 Impact factor: 7.397
Authors: Jennifer Pieper; Anatoly Dubnovitsky; Christina Gerstner; Eddie A James; Mary Rieck; Genadiy Kozhukh; Karolina Tandre; Sara Pellegrino; John A Gebe; Lars Rönnblom; Tatyana Sandalova; William W Kwok; Lars Klareskog; Jane H Buckner; Adnane Achour; Vivianne Malmström Journal: J Autoimmun Date: 2018-05-28 Impact factor: 7.094
Authors: David Chiang; Xintong Chen; Stacie M Jones; Robert A Wood; Scott H Sicherer; A Wesley Burks; Donald Y M Leung; Charuta Agashe; Alexander Grishin; Peter Dawson; Wendy F Davidson; Leah Newman; Robert Sebra; Miriam Merad; Hugh A Sampson; Bojan Losic; M Cecilia Berin Journal: J Allergy Clin Immunol Date: 2018-01-31 Impact factor: 10.793
Authors: Eddie A James; Rebecca E LaFond; Theresa J Gates; Duy T Mai; Uma Malhotra; William W Kwok Journal: J Virol Date: 2013-09-18 Impact factor: 5.103